Strategic funding Crossject has secured substantial funding and recent rights offering activity, signaling strong financial backing and potential for accelerated development and out-licensing of ZEPIZURE and Zeneo platform opportunities.

Regulatory momentum With BARDA contract support of 60 million dollars for ZEPIZURE and ongoing advanced regulatory development, there is an opportunity to position Zeneo-based rescue therapies to U.S. federal procurement channels and hospital networks.

Needle-free advantage ZENO needle-free autoinjector capabilities open routes for partnerships in emergency medical devices, blood banks, and acute care settings where trained staff or layperson administration is critical.

Expanded portfolio A pipeline including rescue therapies for allergic shocks, adrenal insufficiencies, opioid overdose and asthma suggests multi-disease collaboration and co-development deals with pharma partners seeking rescue and emergency treatment platforms.

Global footprint Presence in France and the U.S. along with ongoing development and partner activity (Heights Capital, Cenexi legacy) indicates readiness for cross-border licensing, manufacturing collaborations, and US market entry strategies.